REGULATE-PCI Trial

Summary

The REGULATE-PCI trial compared REG1, a novel factor IXa inhibitor system for patients undergoing percutaneous coronary intervention, with bivalirudin for safety and efficacy outcomes. After just under a year of data collection, an unexpected increase in severe allergic reaction to the REG1 system led to early termination of the trial.

  • REGULATE-PCI
  • REG1 anticoagulation system
  • percutaneous coronary intervention
  • antithrombotic therapy
  • bivalirudin
  • bleeding outcomes
  • stent thrombosis
  • cardiology & cardiovascular medicine clinical trials
  • NCT01848106
View Full Text